Completed PHASE2 INTERVENTIONAL 2-arm NCT01579357

Pharmacokinetics and Metabolic Activation of Capecitabine

Pharmacokinetics and Metabolic Activation of Capecitabine When Given Concomitantly With Oxaliplatin and the Monoclonal Antibody Cetuximab

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Conditions Metastatic Colorectal Cancer

Interventions blood samples

Updated 5 times since 2017 Last updated: Mar 6, 2015 Started: Feb 29, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Arbeitsgemeinschaft medikamentoese Tumortherapie and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arbeitsgemeinschaft medikamentoese Tumortherapie

Data source: Arbeitsgemeinschaft medikamentoese Tumortherapie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salzburg, Austria
• Vienna, Austria